CD4 and neoplasm: Although TIL frequency and the content of CD8+, CD4+ and CD68+ immune cell populations were not altered, tamoxifen selected for ER+ tumor cells driven by the inflammatory NF-κB pathway with elevated stem cell and epithelial mesenchymal transition features.